Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026

Rhea-AI Summary

Nektar (Nasdaq: NKTR) will host an investor call and live webcast on April 20, 2026 at 8:00 am ET / 5:00 am PT to review 52-week topline results from the 16-week extension treatment period of the Phase 2b REZOLVE-AA study of rezpegaldesleukin for severe-to-very-severe alopecia areata.

The company will issue a morning press release, present slides during the webcast, and post the materials and a replay on its investor events page for at least 30 days.

Market Context

This announcement sets a defined catalyst date for 52-week topline results from the REZOLVE-AA Phase...

Analysis

This announcement sets a defined catalyst date for 52-week topline results from the REZOLVE-AA Phase 2b study, extending prior rezpegaldesleukin readouts in alopecia areata. Historical same-tag events, with an average move of 21.65%, show that conference calls tied to topline data have been meaningful trading events. Investors may watch for consistency of long-term efficacy and safety, plus how outcomes fit with plans for later-stage development.

Key Figures

Topline duration: 52-week Extension period: 16-week Trial phase: Phase 2b +4 more

7 metrics

Topline duration 52-week REZOLVE-AA Phase 2b topline results period

Extension period 16-week Extension treatment period within REZOLVE-AA Phase 2b

Trial phase Phase 2b REZOLVE-AA study of rezpegaldesleukin

Call time (ET) 8:00 am ET Investor call on April 20, 2026

Call time (PT) 5:00 am PT Investor call on April 20, 2026

Replay duration 30 days Webcast replay availability after event

Call date April 20, 2026 Scheduled investor conference call

Previous Conferences,clinical trial Reports

2 past events · Latest: Feb 09 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 09	Clinical call announced	Neutral	+51.1%	Scheduled call for 36-week REZOLVE-AD Phase 2b topline results.
Dec 15	Clinical call announced	Neutral	-7.8%	Planned call for 36-week induction REZOLVE-AA Phase 2b topline data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Announcements of conference calls for rezpegaldesleukin topline data have previously produced large, sometimes opposite, price moves, indicating sensitive expectations around clinical readouts.

Recent Company History

Recent history for Nektar centers on rezpegaldesleukin clinical progress and investor communication. Prior same-tag events on Dec 15, 2025 and Feb 9, 2026 also announced conference calls to discuss Phase 2b topline data in alopecia areata and atopic dermatitis, with subsequent ‑7.77% and +51.07% moves, respectively. Today’s announcement of 52‑week topline REZOLVE‑AA data continues this pattern of milestone readouts for the program.

Key Terms

phase 2b, clinical trial, regulatory T-cell, treg, +1 more

5 terms

phase 2b medical

"ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

clinical trial medical

"ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

regulatory T-cell medical

"rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe"

Regulatory T cell (often called a Treg) is a type of white blood cell that acts like a brake or thermostat for the immune system, calming or shutting down immune reactions to prevent damage to healthy tissue. For investors, Tregs matter because drugs or therapies that boost, block, or reprogram these cells can treat a range of conditions—autoimmune disease, transplant rejection, and cancer—so changes in Treg science can drive new drug pipelines and market opportunities.

treg medical

"rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe"

Treg, short for regulatory T cell, is a type of immune cell that acts like a brake on the immune system, calming or suppressing immune responses to prevent excessive inflammation or attack on the body's own tissues. For investors, therapies that boost or block Tregs can change the commercial outlook for drugs treating autoimmune diseases, organ transplant rejection or cancer, because shifting this balance can determine a treatment’s effectiveness and safety.

alopecia areata medical

"rezpegaldesleukin in Alopecia Areata on Monday, April 20, 2026 at 8:00 am ET"

Alopecia areata is an autoimmune condition in which the body's immune system mistakenly attacks hair follicles, causing round patches of hair loss on the scalp or body; severity ranges from small spots to widespread baldness. Investors watch it because successful treatments, clinical trial results, regulatory approvals, or shifts in prevalence can create or shrink markets for drugs and therapies, affecting the value of companies developing remedies—think of it as demand risk and regulatory risk for hair-loss products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, April 19, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52-week topline results from the 16-week extension treatment period of the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Monday, April 20, 2026 at 8:00 am ET / 5:00 am PT. 

Conference Call 
The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK.

The event, the press release and the slides will also be available on the events section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. A replay of the webcast will be available for at least 30 days following the event.

About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

For Investors:

Vivian Wu
628-895-0661

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com
212-915-3820

For Media:

Susan Roberts
LifeSci Communications
202-779-0929
sroberts@lifescicomms.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-hold-conference-call-to-discuss-52-week-topline-results-from-the-16-week-extension-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-april-20-2026-302746623.html

SOURCE Nektar Therapeutics

FAQ

When will Nektar (NKTR) present the 52-week topline results for REZOLVE-AA?

Nektar will present the 52-week topline results on April 20, 2026 at 8:00 am ET via webcast. According to the company, results will be released in a morning press release and discussed on the live investor call and webcast with accompanying slides.

How can investors access Nektar (NKTR) webcast for the REZOLVE-AA 52-week results?

Investors can access the live webcast via the company’s investor events page and a provided webcast link. According to the company, the presentation, press release and slides will also be posted on its events page, with a replay available for at least 30 days.

What data will Nektar (NKTR) discuss on the April 20, 2026 REZOLVE-AA call?

Nektar will review 52-week topline results from the 16-week extension treatment period of its Phase 2b REZOLVE-AA trial. According to the company, the presentation will cover topline findings and supporting slides during the live webcast and press release.

Will Nektar (NKTR) provide slides and a replay for the REZOLVE-AA results presentation?

Yes. Nektar will post slides and offer a replay of the webcast for at least 30 days after the presentation. According to the company, the press release, slides and replay will be available on the events section of its investor website.

What is rezpegaldesleukin and which condition is it being tested for by Nektar (NKTR)?

Rezpegaldesleukin is an investigational Treg proliferator being tested for severe-to-very-severe alopecia areata in the REZOLVE-AA Phase 2b trial. According to the company, the 52-week topline results from the extension period will be presented during the April 20 webcast.